Lucid Diagnostics Share

Lucid Diagnostics Inc. is a medical technology company focused on developing and commercializing products for the early detection of esophageal cancer. The company's core technology, EsoGuard, is a non-endoscopic esophageal DNA test designed to detect Barrett's esophagus, a precancerous condition that increases the risk of developing esophageal adenocarcinoma. By providing a less invasive and more accessible screening method, Lucid Diagnostics aims to improve early detection rates, potentially leading to better patient outcomes and reduced healthcare costs. The company operates within the broader healthcare sector, specifically targeting the gastroenterology and oncology markets with innovative diagnostic solutions. Lucid Diagnostics seeks to transform the management of esophageal cancer through proactive screening and early intervention.